The Novella Clinical team brings an average of 25 years of industry experience to our customers.
Nick Dyer serves as president of Novella Clinical. Mr. Dyer joined in 2011 and served as chief commercial officer where he was responsible for growth and diversification strategies for Novella as well as managing the global business development team and proposals and contracts group.
Prior to joining Novella, Mr. Dyer was vice president, drug development partnerships at Quintiles where he was responsible for the sales, operations and financial performance of partnership activities.
A graduate of the British National Health Service (NHS) general management post graduate program, Mr. Dyer holds a Bachelor’s Degree in Economics from the University of Greenwich, London, and is a Chartered Public Finance Accountant.
Rob King is Novella Clinical’s chief operating officer, where he is responsible for global oversight of the company’s project management, clinical, regulatory and data services.
Prior to joining Novella Clinical in 2006, Mr. King held multiple executive-level positions within the clinical research industry. During that time he managed US and European operations as well as regulatory and quality assurance departments.
Mr. King sits on the Data & Technology Coordinating Center (DTCC) Clinical Research Advisory Board and has been an active member since 2003. He has also served as faculty and an advisory board member at several local universities. Mr. King holds a B.A. from the University of North Carolina Wilmington.
Charles Lambert is chief financial officer for Novella Clinical and oversees all aspects of the company’s financial operations. As an integral part of the executive management team, he develops strategies to maintain Novella’s fiscal health and strong growth trajectory.
Prior to joining Novella Clinical, Mr. Lambert spent 12 years in the healthcare IT sector, serving as CFO for Misys Healthcare Systems and Capario. Throughout his career, he has held numerous executive-level positions within the healthcare, technology and industrial sectors across the US, Europe and Asia. Mr. Lambert graduated from Cambridge University in the United Kingdom and is a qualified Chartered Accountant.
Dr. James Kyle Bryan is chief medical officer for Novella Clinical. He has more than 20 years of experience in drug discovery and development in the pharmaceutical and biotechnology industries in both the sponsor and CRO arenas. Dr. Bryan provides medical and safety leadership to all clinical projects as well as bringing valuable insights into clinical development and regulatory strategy to our clients.
Dr. Bryan is board-certified in medical oncology and hematology, and remains engaged in clinical work, holding an appointment on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center. Prior to joining Novella, Dr. Bryan served as chief medical officer for VentiRx Pharmaceuticals and vice president of medical affairs for Seattle Genetics.
Dr. Bryan received a B.S. in Biochemistry and an M.D. from Louisiana State University. He completed his fellowship in hematology and oncology at the University of Washington.
Dr. Chris Smyth is executive vice president of the Oncology Division at Novella Clinical. He is responsible for developing and implementing strategic direction for the Oncology business unit and provides executive oversight for all clinical projects to ensure successful execution.
Dr. Smyth has more than 20 years’ oncology research and development experience in the pharmaceutical industry. He has led clinical research organizations and biopharmaceutical companies in both Europe and the US.
Dr. Smyth earned his Ph.D. in Reproductive Biology from the University of Edinburgh and an M.B.A. from Henley Management College, United Kingdom.
Tina Siemens is responsible for the global clinical monitoring division at Novella Clinical. With more than 20 years of industry experience, Ms. Siemens brings an extensive background in clinical trial management, project management and clinical monitoring. Most recently she served as Vice President, North American Clinical Operations, for a global clinical research organization. Ms. Siemens earned a B.S. in Nursing from the University of North Carolina at Chapel Hill.
Rob Stallings leads Novella Clinical Resourcing (NCR), which delivers customized staffing and functional outsourcing services to the pharmaceutical, medical device and biotechnology industries in North America and Europe. With more than 20 years of healthcare and pharmaceutical resourcing and outsourcing experience, Mr. Stallings provides both strategic guidance and day-to-day operational leadership for NCR’s global staff.
Prior to joining NCR, Mr. Stallings served as executive vice president at a major US-based clinical staffing firm with responsibility for the company’s overall operations. He also worked for a leading health care recruiting firm as a physician recruiter and held various leadership roles in operations, business development and communications.
Anusha Bala, BSc, LLB, is responsible for leading Novella Clinical’s global regulatory affairs department. She oversees regulatory clinical research projects, safety reporting for oncology and medical device customers, and provides the project team with guidance, training and strategic planning. Ms. Bala has more than 15 years of regulatory affairs experience globally across many therapeutic areas including oncology, CNS and respiratory research. Prior to joining Novella, Ms. Bala held senior regulatory affairs roles at a variety of organizations including the Medicines and Healthcare products Regulatory Agency (MHRA) and two global CROs. Ms. Bala has a BSc in medicinal chemistry and was academically qualified as a barrister in 2007.
David Novotny is senior vice president of Novella Clinical’s Medical Device & Diagnostics Division and has more than 17 years of clinical research experience in hospital, CRO and medical device and biopharma environments. He is responsible for the oversight, strategy and operational success of all medical device and diagnostics sponsor programs globally, including clinical execution and governance management. Prior to joining Novella in 2007, Mr. Novotny served as the US head of operations for a global vascular device company in Chelsea, England.
Mr. Novotny’s therapeutic areas of experience include cardiovascular, vascular, gastroenterology, endocrinology, urology, CNS, orthopedic, neurology, wound care and dermatology. He is a graduate of the University of Iowa with a Bachelor of Science in Exercise Science and an emphasis on physiology and business management.
Darcee Duke Strube is senior vice president of the Dermatology Division at Novella Clinical. She is responsible for facilitating business alliances around the globe and driving strategic direction for the Dermatology Division business unit. Ms. Strube has more than 35 years of experience in various clinical operations and business development positions in sponsor, CRO and site organizations. Prior to joining Novella in 2016, she held key roles in the Clinical Trials Division of TKL Research.
Ms. Strube has extensive expertise in the therapeutic areas of acne, actinic keratosis, onychomycosis, psoriasis, rosacea and wound healing, among others. She earned a Bachelor of Science in Biology from Fairleigh Dickinson University in New Jersey.